心血管随机试验与多中心观察性研究结局指标的系统综述与证据映射
研究发现主要结局使用复合指标的比例从2013年的49%上升至2018年峰值85%,次要结局数量增加,且心血管死亡、心肌梗死和卒中的定义在各研究间存在异质性。作者呼吁标准化心血管结局指标的使用。
要点
- 复合主要结局使用率从2013年49%升至2018年峰值85%
- 随机试验次要结局中位数从3个增至8个,观察性研究从0个增至7个
- 心血管死亡、心肌梗死和卒中的定义在各研究间存在异质性
核心结论
- 高被引期刊心血管研究的主要复合结局和次要结局使用增加,但主要结局定义存在异质性,需要标准化方法。
主要发现
- 最常报告的主要结局指标是复合终点(63%),其最常见组分是心肌梗死(58%)。
- 使用复合主要结局的研究比例从2013年的49%上升至2018年峰值85%。
- 从2013年到2023年,每项研究的次要结局指标中位数在随机试验中从3个增至8个,在观察性研究中从0个增至7个。
- 心血管死亡、心肌梗死和卒中的定义在各研究间存在差异。
- 研究涉及冠心病(51%)、心肌病/心力衰竭(22%)、心律失常(15%)、瓣膜性心脏病(11%)和其他心血管疾病(1%),45%研究器械,48%由工业资助。
临床怎么用
- 解读心血管研究时需注意主要复合结局的组分定义可能不同,次要结局数量增加可能影响结果解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Outcome measure choice and definition can determine the result of the study. We describe outcome measures and their definitions for cardiovascular studies in highly cited medical journals. METHODS: Cardiovascular phase III or IV randomised clinical trials (RCTs) or multicentre observational studies published in the New England Journal of Medicine, Lancet or Journal of the American Medical Association between 1 January 2013 and 6 June 2024 from Embase and Ovid Medline were included. Two independent reviewers selected the studies and extracted the primary and secondary outcome measures from each publication. RESULTS: 386 studies (83% RCTs; 17% observational) representing 10 699 147 participants were included. Studies investigated coronary heart disease (51%), cardiomyopathy/heart failure (22%), heart rhythm disease (15%), valvular heart disease (11%) and 'other' cardiovascular diseases (1%), with 45% investigating a device and 48% funded by industry. The most frequently reported primary outcome measure was a composite (63%), the most frequent component of which was myocardial infarction (58%). The use of a composite for the primary outcome measure increased from 49% of studies in 2013 to a peak of 85% in 2018. From 2013 to 2023, the median number of secondary outcome measures per study increased for RCTs (3-8) and observational studies (0-7). Definitions for cardiovascular mortality, myocardial infarction and stroke varied across the studies. CONCLUSIONS: For cardiovascular studies published in highly cited journals, there has been an expansion in the use of primary composite outcome measures and secondary outcome measures, with heterogeneity in the definition of primary outcome measures. A standardised approach to the use of cardiovascular outcomes measures is required.
引用
- Bhatty A, Wilkinson C, Aktaa S, et al. Outcome measures for randomised clinical trials and multicentre observational studies of cardiovascular diseases published in major clinical journals: systematic review and evidence mapping. Heart. 2025. PMID: 40533147. doi:10.1136/heartjnl-2025-326045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。